Please login to the form below

Not currently logged in
Email:
Password:

Dr Steven Gillis joins Shire’s board of directors

He will sit on the pharma firm's science and technology and its remuneration committee

Steven Gillis - ShireShire has appointed managing director of Arch Venture Partners Dr Steven Gillis to its board of directors.

Dr Gillis will join the Ireland-based pharma firm on October 1, becoming a member of its science and technology committee as well as its remuneration committee.

Commenting on his appointment, he said: “Shire has a clear and ambitious patient-focused vision for the future and I look forward to the opportunity to help them achieve it.”

A trained immunologist, Dr Gillis has experience in the life sciences industry through his work at Arch, which provides venture capital to firms working on new life sciences technologies.

Prior to this role, Dr Gillis was a founder and director of Corixa Corporation, which was acquired by GlaxoSmithKline in 2005 (GSK), and he was previously a founder and director of Immunex Corporation.

He currently holds a number of other roles, including as a non-executive director of New Zealand-based biotech Genesis Research and Development Corporation.

10th September 2012

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....

Infographics